Acadia Pharma ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Trading Halts

Aegis Capital Affirms Acadia Pharma (ACAD) at 'Buy' Following Positive FDA Panel Review; Sees Nuplazid Approval SoonMarch 30, 2016 10:44 AM Needham & Company Remains Bullish on Acadia Pharma (ACAD) Following Positive FDA Vote on Nuplazid March 30, 2016 6:49 AM Acadia Pharma (ACAD) Surges 25% as Trading ResumesMarch 29, 2016 5:52 PM Acadia Pharma (ACAD) Announces Favorable FDA Panel Vote on NUPLAZID for the Treatment of Psychosis Associated with Parkinson's DiseaseMarch 29, 2016 5:14 PM FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the RisksMarch 29, 2016 5:13 PM Acadia Pharma (ACAD) wins FDA panel backing for Nuplazid - BloombergMarch 29, 2016 3:37 PM Acadia Pharma (ACAD) adequately characterized the safety profile of NUPLAZID - FDA PanelMarch 29, 2016 3:19 PM Acadia Pharma's (ACAD) NUPLAZID Seen Effective in Parkinson's - FDA PanelMarch 29, 2016 2:55 PM Acadia Pharma (ACAD) Said Facing 'Tough' Nuplazid Efficacy Questions from FDA PanelMarch 29, 2016 10:14 AM Acadia Pharma (ACAD) Halted Ahead of FDA PDAC Review of NUPLAZID March 29, 2016 7:05 AM ACADIA Pharmaceuticals Stock Trading Halted TodayMarch 29, 2016 7:05 AM Acadia Pharma (ACAD) trading halted with news pendingMarch 29, 2016 7:00 AM